This specification relates to a process for preparing fucose from a human milk oligosaccharide (“HMO”) comprising a fucose moiety, as well as L-fucose compositions prepared by such a process.

This specification relates to a process for preparing fucose from a human milk oligosaccharide (“HMO”) comprising a fucose moiety, as well as L-fucose compositions prepared by such a process.

A method for preparing needle coke for ultra-high power (UHP) electrodes from heavy oil is provided. In this method, heavy oil is used as a raw material. The size exclusion chromatography (SEC) is conducted with polystyrene (PS) as a packing material to separate out specific components with a relative molecular weight of 400 to 1,000. The ion-exchange chromatography (IEC) is conducted to remove acidic and alkaline components to obtain a neutral raw material. The neutral raw material is subjected to two-stage consecutive carbonization to obtain green coke, and the green coke is subjected to high-temperature calcination to obtain the needle coke for UHP electrodes. The needle coke has a true density of more than 2.13 g/cm.sup.3 and a coefficient of thermal expansion (CTE) of ≤1.15×10.sup.−6/° C. at 25° C. to 600° C.

A method for preparing needle coke for ultra-high power (UHP) electrodes from heavy oil is provided. In this method, heavy oil is used as a raw material. The size exclusion chromatography (SEC) is conducted with polystyrene (PS) as a packing material to separate out specific components with a relative molecular weight of 400 to 1,000. The ion-exchange chromatography (IEC) is conducted to remove acidic and alkaline components to obtain a neutral raw material. The neutral raw material is subjected to two-stage consecutive carbonization to obtain green coke, and the green coke is subjected to high-temperature calcination to obtain the needle coke for UHP electrodes. The needle coke has a true density of more than 2.13 g/cm.sup.3 and a coefficient of thermal expansion (CTE) of ≤1.15×10.sup.−6/° C. at 25° C. to 600° C.

Doxorubicin is extracted from blood using anionic material, such as a resin comprising sulfonated polystyrene divinylbenzene beads, and polyethersulfone membrane, or both. After exposing the resin and/or membrane to blood in order to remove doxorubicin therefrom, the doxorubicin maybe extracted from the resin and/or membrane by exposing the material to an extraction solution, sonicating the extraction solution to enhance release of the doxorubicin, and repeating the exposure and sonication in order to remove substantially all of doxorubicin from the resin.

Doxorubicin is extracted from blood using anionic material, such as a resin comprising sulfonated polystyrene divinylbenzene beads, and polyethersulfone membrane, or both. After exposing the resin and/or membrane to blood in order to remove doxorubicin therefrom, the doxorubicin maybe extracted from the resin and/or membrane by exposing the material to an extraction solution, sonicating the extraction solution to enhance release of the doxorubicin, and repeating the exposure and sonication in order to remove substantially all of doxorubicin from the resin.

The present invention relates to methods of processing lignocellulosic material to obtain hemicellulose sugars, cellulose sugars, lignin, cellulose and other high-value products. Also provided are hemicellulose sugars, cellulose sugars, lignin, cellulose, and other high-value products.

The present invention relates to methods of processing lignocellulosic material to obtain hemicellulose sugars, cellulose sugars, lignin, cellulose and other high-value products. Also provided are hemicellulose sugars, cellulose sugars, lignin, cellulose, and other high-value products.

Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.

Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.